ZYUS Life Sciences Corp. is a Canadian-based life sciences company. The company is headquartered in Saskatoon, Saskatchewan. The company went IPO on 2000-10-18. Its lead research program is focused on developing a purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for the treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management. Both pre-clinical and non-clinical studies have been conducted on this formulation and patent applications have been filed.
Follow-Up Questions
What is the price performance of ZLSCF stock?
The current price of ZLSCF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for ZYUS Life Sciences Corp?
ZYUS Life Sciences Corp belongs to Pharmaceuticals industry and the sector is Health Care
What is ZYUS Life Sciences Corp market cap?
ZYUS Life Sciences Corp's current market cap is $0
Is ZYUS Life Sciences Corp a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for ZYUS Life Sciences Corp, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
